Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP

Author:

Mykkänen Anssi J.H.123ORCID,Tarkiainen E. Katriina123,Taskinen Suvi13,Neuvonen Mikko13ORCID,Paile‐Hyvärinen Maria123ORCID,Lilius Tuomas O.123ORCID,Tapaninen Tuija123ORCID,Klein Kathrin45,Schwab Matthias4567ORCID,Backman Janne T.123ORCID,Tornio Aleksi123ORCID,Niemi Mikko123ORCID

Affiliation:

1. Department of Clinical Pharmacology University of Helsinki Helsinki Finland

2. Department of Clinical Pharmacology, HUS Diagnostic Center Helsinki University Hospital Helsinki Finland

3. Individualized Drug Therapy Research Program University of Helsinki Helsinki Finland

4. Dr Margarete Fischer‐Bosch Institute of Clinical Pharmacology Stuttgart Germany

5. University of Tübingen Tübingen Germany

6. Department of Clinical Pharmacology University of Tübingen Tübingen Germany

7. Department of Biochemistry and Pharmacy University of Tübingen Tübingen Germany

Abstract

In a genome‐wide association study of atorvastatin pharmacokinetics in 158 healthy volunteers, the SLCO1B1 c.521T>C (rs4149056) variant associated with increased area under the plasma concentration‐time curve from time zero to infinity (AUC0–∞) of atorvastatin (P = 1.2 × 10−10), 2‐hydroxy atorvastatin (P = 4.0 × 10−8), and 4‐hydroxy atorvastatin (P = 2.9 × 10−8). An intronic LPP variant, rs1975991, associated with reduced atorvastatin lactone AUC0–∞ (P = 3.8 × 10−8). Three UGT1A variants linked with UGT1A3*2 associated with increased 2‐hydroxy atorvastatin lactone AUC0–∞ (P = 3.9 × 10−8). Furthermore, a candidate gene analysis including 243 participants suggested that increased function SLCO1B1 variants and decreased activity CYP3A4 variants affect atorvastatin pharmacokinetics. Compared with individuals with normal function SLCO1B1 genotype, atorvastatin AUC0–∞ was 145% (90% confidence interval: 98‐203%; P = 5.6 × 10−11) larger in individuals with poor function, 24% (9‐41%; P = 0.0053) larger in those with decreased function, and 41% (16‐59%; P = 0.016) smaller in those with highly increased function SLCO1B1 genotype. Individuals with intermediate metabolizer CYP3A4 genotype (CYP3A4*2 or CYP3A4*22 heterozygotes) had 33% (14‐55%; P = 0.022) larger atorvastatin AUC0–∞ than those with normal metabolizer genotype. UGT1A3*2 heterozygotes had 16% (5‐25%; P = 0.017) smaller and LPP rs1975991 homozygotes had 34% (22‐44%; P = 4.8 × 10−5) smaller atorvastatin AUC0‐∞ than noncarriers. These data demonstrate that genetic variation in SLCO1B1, UGT1A3, LPP, and CYP3A4 affects atorvastatin pharmacokinetics. This is the first study to suggest that LPP rs1975991 may reduce atorvastatin exposure. [Correction added on 6 April, after first online publication: An incomplete sentence (“= 0.017) smaller in heterozygotes for UGT1A3*2 and 34% (22%, 44%; P × 10−5) smaller in homozygotes for LPP noncarriers.”) has been corrected in this version.]

Funder

European Research Council

Sigrid Juséliuksen Säätiö

Robert Bosch Stiftung

Publisher

Wiley

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3